Development of outreach, genetic counselling and registry programmes similar to those offered by the WFH and through our

national member organizations (NMOs) for haemophilia is fundamentally BMS-354825 datasheet important to close this care gap for women with bleeding disorders. In addition, HTCs and NMOs will need to be prepared to support the psychological and social implications associated with carrier testing and diagnosis. A number of outreach programmes (such as Women Bleed Too in the UK [22], Project Red Flag in the US [23], and the women’s programme of the Canadian Hemophilia Society [24]) have been created to raise awareness about women with bleeding disorders and to improve the quality of care and life for these Silmitasertib order women. However, to date these programmes have not been tested or optimized for use in developing countries or within diverse cultural communities. Traditional outreach techniques, such as family histories, may not be optimal approaches to identify women with bleeding disorders other than haemophilia. Innovative strategies and tools are needed to reach vulnerable populations. To address this need the WFH is building on

a WFH development programme that launched with the Lebanese Haemophilia Association and Ministry of Health in 2006. Following the diagnosis of haemophilia cases in the Bekaa Valley and Akkar regions, a new pilot project to identify VWD patients has been initiated working through the regional community health centres of the Ministry of Health [25]. Other pilot outreach projects are being launched in Egypt and Latin America. A unique pilot outreach effort has been conducted in collaboration with the World Health Organization (WHO) to raise awareness of the risks of PPH and maternal death. In the context of this interregional consultation within the Gulf States on the role of nurses and midwives

in ensuring safe clinical transfusion and patient safety, the WFH highlighted the critical role of the clinical management of patients with haemorrhage and bleeding disorders [26]. Given the many settings Ibrutinib cell line in which women will present with bleeding complications, multi-faceted outreach and educational approaches are required. The results of these initiatives will be evaluated to inform planning and performance of future WFH global outreach programmes. Having recognized the critical importance and challenges of fully incorporating women with bleeding disorders within the WFH global family, the next crucial steps include the development of outreach and registry programmes which can be adapted globally to accelerate the identification of women to educate and guide them to the appropriate clinical care setting. In parallel, it is important to develop the education and training capacity within WFH NMOs as well as clinical expertise within the HTC network.